Wei Qiang, Chen Dong-Sheng, Liu Yuan-Hua
Ultrasonic Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co. Ltd., Nanjing, China.
Front Oncol. 2022 Mar 10;12:853211. doi: 10.3389/fonc.2022.853211. eCollection 2022.
Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with mutation. In publicly available niraparib treatment-related adverse events, gastrointestinal disorders and hematological toxicities were most commonly reported with manageable safety profile. Herein, we first describe a severe and never-reported pulmonary embolism (PE) associated with the use of niraparib in a patient with mutation advanced high-grade serous ovarian cancer and received anticoagulant therapy after PE. There have been no reports of PE caused by the use of niraparib in patients with advanced high-grade serous ovarian cancer; knowledge of the occurrence of PE after the use of niraparib may assist other clinicians in managing this rare but potentially serious toxic effect.
尼拉帕利是一种口服、强效、高度选择性的聚（ADP - 核糖）聚合酶（PARP）抑制剂，对于铂类化疗部分缓解的卵巢癌患者的维持治疗具有显著的临床益处，尤其是在具有[具体突变名称]突变的患者中。在公开的尼拉帕利治疗相关不良事件中，胃肠道疾病和血液学毒性最为常见，且安全性可控。在此，我们首次描述了一例患有[具体突变名称]突变的晚期高级别浆液性卵巢癌患者在使用尼拉帕利后发生的严重且从未报道过的肺栓塞（PE），该患者在发生肺栓塞后接受了抗凝治疗。在晚期高级别浆液性卵巢癌患者中，尚无使用尼拉帕利导致肺栓塞的报道；了解使用尼拉帕利后发生肺栓塞的情况可能有助于其他临床医生处理这种罕见但潜在严重的毒性作用。
